Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Pozzuoli – page 28

1 231 clinical trials in Pozzuoli, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pozzuoli at a glance
1 231
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 231 trials in Pozzuoli

Open in trial search

Radiologically isolated syndrome

Recruiting

Study of BCG Vaccine and Sodium Chloride for Patients with Radiologically Isolated Syndrome (RIS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S

Hormone-refractory prostate cancer

Recruiting

Study Comparing Docetaxel and Androgen Receptor-Targeted Agents (Abiraterone or Enzalutamide) for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Metastases to central nervous system

Recruiting

Study of Ipilimumab and Nivolumab with or without Radiotherapy for Patients with Melanoma Brain Metastases

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Melanoma Institute Australia

Non-small cell lung cancer stage IV

Recruiting

Study Comparing Atezolizumab Alone and Atezolizumab with Bevacizumab for First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Ricerca Traslazionale

Ovarian cancer stage IV+1

Recruiting

Study on Letrozole vs. Chemotherapy (Carboplatin and Paclitaxel) for Patients with Advanced Low-Grade Serous Ovarian Cancer with Hormone Receptors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Ente Ospedaliero Ospedali Galliera Di Genova

Extra-osseous Ewing's sarcoma+5

Recruiting

Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Acute myeloid leukaemia

Recruiting

Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amsacrine
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Glomerulonephritis minimal lesion+1

Recruiting

Study on Frexalimab, SAR442970, and Rilzabrutinib for Patients Aged 16-75 with Focal Segmental Glomerulosclerosis or Minimal Change Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Endometrial cancer+13

Recruiting

Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Hodgkin's disease

Recruiting

Study of Nivolumab for Early Stage Hodgkin Lymphoma in Patients with Good Prognosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Medical University Of Gdansk

Squamous cell carcinoma of skin

Recruiting

Study on Cemiplimab for Patients with High-Risk Stage III/IV Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Fondazione Melanoma Onlus

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Pozzuoli

What the registry says about research in the country

01 Neoplasms

Clinical trial activity in Località la Schiana, Pozzuoli is strongly focused on cancer research, with studies examining how to improve treatment options for several advanced solid tumors. The main goal is to test new therapeutic strategies and refine existing combinations for better disease control and patient outcomes.

  • Colorectal cancer, including metastatic and unresectable forms
  • Metastatic castration-resistant prostate cancer
  • Metastatic renal cell carcinoma
  • Breast cancer with hormone receptor-positive, HER2-negative disease

These studies are exploring more effective ways to slow progression, overcome treatment resistance, and improve survival in patients with advanced neoplasms.

02 Digestive System Diseases

Several trials in this site concentrate on digestive system cancers, especially advanced colorectal cancer. Research is centered on evaluating treatment effectiveness and finding better options for patients whose disease has already progressed or carries specific genetic changes.

  • RAS-mutant metastatic colorectal cancer
  • RAS/BRAF wild-type metastatic colorectal cancer
  • Unresectable left-sided metastatic colorectal cancer
  • Patients with metastatic colorectal cancer

Across these studies, the focus is on improving tumor response, extending disease control, and identifying which patients may benefit most from targeted treatment approaches.

03 Analytical, Diagnostic and Therapeutic Techniques and Equipment

This research landscape also includes therapeutic techniques aimed at improving how treatments are delivered and how response is monitored. The trials are not only testing active therapies, but also looking for better ways to understand resistance, safety, and treatment benefit in real-world patients.

  • Biomarker research for resistance and treatment monitoring
  • Safety and tolerability comparisons between treatment strategies
  • Quality of life assessments during therapy
  • Therapy optimization in advanced cancer care

In this part of the research portfolio, investigators in Pozzuoli are helping shape more precise and patient-centered cancer care.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.